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been	 associated	with	 a	higher	 risk	of	 developing	AF	as	well	 as	 an	
effective	treatment	of	AF,	but	evidence	is	inconsistent.9,11,14	In	the	
general	 population,	 various	 treatment	 options	 for	 AF	 have	 exten‐
sively	been	studied,	of	which	pulmonary	vein	isolation	(PVI)	has	been	
accepted	as	a	safe	and	effective	procedure.15,16	Less	is	known	about	
the	 preferred	 treatment	 strategy	 for	 AF	 in	 patients	with	 an	ASD,	



























Radboud	 University	 Medical	 Center	 Nijmegen	 (METC	 number:	
2018‐4860).
2.1 | Inclusion












All	 procedures	were	 performed	 under	 general	 anesthesia	 or	 con‐
scious	 sedation,	 with	 transesophageal	 echocardiography	 (TEE)	 to	
exclude	thrombi	in	the	left	atrium.
After	gaining	right	femoral	vein	access	and	sheath	placement,	
a	 steerable	 decapolar	 diagnostic	 catheter	was	 positioned	 in	 the	
coronary	 sinus.	 Access	 to	 the	 left	 atrium	 and	PVs	was	 obtained	
using	direct	wire	passage	through	the	septal	defect.	In	case	if	this	
could	 not	 be	 achieved,	 transseptal	 puncture	 (single	 or	 double)	
under	fluoroscopic	and	TEE	guidance	would	have	been	performed.	
During	 the	procedure,	 the	patient	heparin	was	administered	tar‐
geting	 an	 activated	 clotting	 time	 >300	 seconds.	 PVI	 using	 cryo	
energy	was	performed	using	 the	 second	generation	 cryoballoon	
(Medtronic,	Minneapolis,	MN,	USA)	 in	 combination	with	 the	12‐
French	 steerable	 sheath	 (Medtronic,	Minneapolis,	MN,	USA).	All	
the	 PVs	 were	 mapped	 with	 an	 inner	 lumen	 mapping	 catheter.	
Every	vein	was	treated	with	at	least	two	applications.	The	freeze	
cycles	 were	 180	 seconds.	 Balloon	 size	 of	 the	 cryoballoon	 was	
28	mm	in	all	cases.	Phrenic	nerve	palsy	was	monitored	during	ab‐






left‐	 and	 right‐sided	 PV	 pairs.	 PVI	was	 confirmed	 using	 a	 steer‐
able	 multi‐electrode	 lasso	 catheter.	 No	 additional	 lines	 or	 focal	
lesions	were	made.	After	confirming	isolation	of	the	veins	an	over	
the	wire	change	to	an	Amplatzer	Torque	45°	delivery	system	was	
performed	 for	 the	 ASD	 closure.	 After	 TEE	 sizing,	 the	 appropri‐
ate	closure	device	was	delivered,	using	 fluoroscopy	guidance,	 to	
close	 the	defect.	Using	 contrast	 injection,	 residual	 defects	were	
ruled	out	and	after	confirmation	of	a	good	and	stable	position,	the	
implantation	 tool	was	 released	 and	 retracted.	 The	 day	 after	 the	
procedure,	a	transthoracic	echocardiogram	(TTE)	was	performed	







after	 ablation,	 but	 also	 symptom	driven	 consultation.	As	 recom‐
mended	 in	current	guidelines,	a	blanking	period	of	three	months	
after	 PVI	was	 applied.15	Oral	 anticoagulation	was	 continued	 for	





complications,	 procedure	 time,	 and	duration	of	hospital	 admission	
were	collected.
3  | RESULTS
Between	 September	 2016	 and	 August	 2017,	 five	 patients	 (four	
female,	 mean	 age	 58	 ±	 3	 years)	 were	 eligible	 for	 the	 combined	
procedure	of	PVI	and	ASD	closure;	baseline	and	procedural	char‐
acteristics	are	listed	in	Table	1.	All	patients	had	symptomatic	par‐
oxysmal	AF	with	 a	median	 time	 from	onset	 of	 symptoms	 to	 the	
procedure	of	26	months,	ranging	from	2	to	54	months.	The	max‐
imal	 CHA₂DS₂‐VASc	 score	was	 2	 and	 all	 patients	 used	 a	NOAC.	
Transseptal	access	for	PVI	was	obtained	via	wire	passage	through	
TA B L E  1  Clinical‐,	procedural‐	and	follow‐up	data
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age	(years) 58 49 59 66 58
Sex F F F F M
Comorbidity M.	Graves None Hypertension Hypercholesteromia Hypertension
BMI 25 24 24 29 26
ASD	size	(mm) 16 15 19 18 4 and 1
RVEDD	(inlet,mm) 47 43 40 43 52
Left	ventricle	systolic	function Normal Normal Normal Normal Normal
LVEDD	(mm) 46 43 38 35 50
Valve	disease No No No No No
left	atrial	size	(m1/m2) 29 43 32 25 48
duration	of	AF	(months)a  26 2 42 54 25
CHADSVASC	score 2 1 2 2 1
Anticoagulation Apixaban	bid Edoxaban	od Dabigatran	bid Apixaban	bid Apixaban	bid
Antiarrythmic	drug propranolol metoprolol nebivolol sotalol flecainide
PVI	technique Cryoballoon Cryoballoon Cryoballoon Cryoballoon RF	point‐by‐point
Balloon	size	(mm) 28 28 28 28 n.a.
Acute	isolation	pulmonary	veins Yes Yes Yes Yes yes
ASD	closure	device Amplatzer Amplatzer Amplatzer Amplatzer Gore	Cardioform	
Septal	Occluder
Size	closure	device	(mm) 28 18 24 20 30
Total	procedure	time	(min) 153 183 236 153 218
Fluoroscopy	time	(min) 24 Unknown 23 24 27
Hospital	admission	(days) 1 1 1 1 2
Complication Groin	hematoma No No Groin	hematoma No
AF	recurrence	at	3months No Yes No No No
AF	recurrence	at	6	months No Yes No No No
AF	recurrence	at	12	months No No No No Yes
Abbreviations:	LVEDD,	left	ventricle	end	diastolic	dimension;	PVI,	pulmonary	vein	isolation;	RVEDD,	right	ventricle	end	diastolic	dimension.
aDuration	defined	as	time	in	months	of	diagnosed	atrial	fibrillation	before	the	procedure.	










performed	on	 the	 first	postprocedural	day	 confirmed	 stable	po‐
sition	 of	 the	 closure	 device	 and	 absence	 of	 pericardial	 effusion	
in	 all	 patients.	 Four	 patients	 were	 discharged	 on	 the	 first	 post‐
procedural	 day	 and	one	on	 the	 second.	 Every	patient	 continued	
to	use	oral	anticoagulants.	At	the	end	of	the	12‐month	follow‐up	
period,	three	patients	were	free	from	AF	recurrence.	One	patient	











closure	 in	 symptomatic	 AF	 patients	 and	 an	 indication	 for	 ASD	
closure	 is	 feasible	 and	 safe.	During	 the	 12‐month	 follow‐up	 pe‐
riod	 three	 of	 five	 patients	were	 free	 from	AF	 recurrence	 (60%).	
Interestingly,	both	patients	with	AF	recurrences	had	an	enlarged	
left	 atrium,	 known	 as	 a	 predictor	 of	 AF	 in	 general,	 and	 of	 PVI	
failure.26,27
Our	recurrence	rate	 is	comparable	to	the	rate	described	 in	pa‐
tients	 undergoing	PVI	with	 an	 uncorrected	ASD	 (44%).23	 Another	
study	 showed	 a	 comparable	 recurrence	 rate	 after	 PVI	 in	 patients	
with	a	previously	closed	ASD	(44%).20
F I G U R E  1  X‐ray	images	of	a	procedure.	Direct	wire	passage	through	the	defect	(A),	isolation	of	the	left	inferior	pulmonary	vein,	in	this	
case	with	CRYOballoon	(B)	and	measuring	and	placing	the	ASD	closure	device	(C	and	D)











a	 combined	 procedure.	Our	 procedure	 time	 is	 only	 slightly	 longer	
than	the	mean	PVI	procedure	time	of	124	(cryoballoon)	and	141	min‐
utes	 (RF)	 in	the	FIRE	and	 ICE	study	and	the	162	 (cryoballoon)	and	














actual	 decision	 on	 performing	 the	 redo	procedure	will	 depend	on	
severity	of	symptoms	and	will	be	a	joint	decision	of	the	patient	and	
physician.	Nevertheless,	 if	 all	 patients	with	AF	 recurrences	would	
opt	for	a	redo	procedure,	four	patients	will	be	subjected	to	the	com‐
plication	risks	of	a	redo	procedures.






will	 even	 have	 undergone	 three	 procedures,	 when	 redo	 PVI	 and	





F I G U R E  2  TEE	images	of	an	ASD	closure	procedure.	The	septal	defect	(arrow	in	A),	with	clear	left‐to‐right	shunting	(B).	Measuring	the	
defect	(C)	and	the	closure	device	covering	the	defect	(D)
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